AMGN Amgen Inc.

Healthcare · Drug Manufacturers - General

4 · Weak Momentum 10.0 · Strong Watch 14y streak

442.36

+4.02%

About the company

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Website Annual reports (10-K)

2.28%

62.53%

10.08

238.7B

27.44

16.12

350.69

52-week range

442

low 270 high 443

Dividend deep dive

Amgen Inc. is a Healthcare sector company in the Drug Manufacturers - General industry. It currently offers a dividend yield of 2.43%. This yield is below its 5-year low of 2.99% and its 5-year average of 3.16%, suggesting it is overvalued by Yield Theory. The company holds a momentum score of 9.0 and a value score of 3.3. Its overall rating score is 4.0, and dividend safety status is classified as "watch".

Dividend history

Amgen has a dividend increase streak of 14 years, qualifying it as a CCC Contender. Over the last three years, the dividend has grown at a CAGR of 7.05%, and over the last five years, the CAGR was 8.27%. Annual dividend payments have progressed from 2.44 USD in 2014 to 8.52 USD in 2023, with projected payments of 9.00 USD in 2024 and 9.52 USD in 2025. The company pays dividends quarterly in February, May, August, and November.

Dividend safety

Amgen's dividend safety status is currently marked as "watch." The company's payout ratio is 62.57%, based on its EPS of 16.11 USD and an annual dividend of 10.08 USD.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 17 Aug 2026 · Information, not financial advice.